Select Advanced Solid Tumors Clinical Trial
Official title:
Phase 1, First-in-Human Study to Assess the Safety, Tolerability and Anti-tumor Activity of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors
CDR404 is a highly potent and specific T-cell engaging bispecific and bivalent antibody designed for the treatment of cancers positive for the tumor-associated antigen melanoma-associated antigen 4 (MAGE-A4). This is a first-in-human study designed to evaluate the safety, tolerability, and preliminary anti-tumor activity of CDR404 in adult patients who have the appropriate germline human leukocyte antigen HLA-A*02:01 tissue marker and whose cancer is positive for MAGE-A4.
The CDR404-001 Phase 1 study will enrol patients with locally advanced, unresectable or metastatic tumors expressing MAGE-A4, which include advanced solid tumors, and will be conducted in multiple phases: 1. To identify the maximum tolerated dose (MTD) and pharmacologically effective dose range (PEDR) for CDR404 2. To assess preliminary evidence of anti-tumor activity of CDR404 3. To characterise the pharmacokinetics of CDR404 4. To characterise the immunogenicity of CDR404 5. To assess translational biomarkers ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03973333 -
Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab
|
Phase 1/Phase 2 | |
| Completed |
NCT02705482 -
A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors
|
Phase 1 | |
| Terminated |
NCT03515551 -
Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04262466 -
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
|
Phase 1/Phase 2 |